Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

Zydus Lifesciences Limited is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.267000
forwardPE 23.637335
debtToEquity 42.242000
earningsGrowth 0.087000
revenueGrowth 0.162000
grossMargins 0.731380
operatingMargins 0.184670
trailingEps 50.130000
forwardEps 46.595780

ZYDUSLIFE's current ratio of 1.267 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that ZYDUSLIFE is financially well-prepared to meet its liabilities without difficulty.
ZYDUSLIFE's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
Zydus Lifesciences Limited's lower forward EPS compared to its trailing EPS indicates that the company may be less profitable in the upcoming year. This suggests a potential slowdown in earnings, which could be a sign of weaker financial performance ahead.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

The price of ZYDUSLIFE has often been situated close to the lower end of projections. This consistent trend may signal difficulties for the company in achieving investor expectations for future performance.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


ZYDUSLIFE had 2 buy transactions, with market price at 995.1749877929688 per share.During the period under consideration, no buy transactions took place.ZYDUSLIFE has experienced more selling activity at current price levels, which could suggest a bearish outlook. If the trend of increased selling continues, it may result in further price declines for the stock.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


Analysts' buy bias for ZYDUSLIFE signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to ZYDUSLIFE, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.